Pro-inflammatory Cytokines and Oxidized Low-Density-Lipoprotein in Patients With Fibromyalgia
Yıl: 2019 Cilt: 34 Sayı: 2 Sayfa Aralığı: 123 - 129 Metin Dili: İngilizce DOI: 10.5606/ArchRheumatol.2019.6733 İndeks Tarihi: 28-01-2020
Pro-inflammatory Cytokines and Oxidized Low-Density-Lipoprotein in Patients With Fibromyalgia
Öz: Objectives: This study aims to evaluate the differences in serum levels of tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), (IL-8),and oxidized low-density lipoprotein (Ox-LDL) between female fibromyalgia (FM) patients and healthy females and also to examine a possiblerelationship between the cytokines/biomarker and the severity of pain and clinical features of FM.Patients and methods: This case-control study included 48 female patients (mean age 26.51±6.98 years; range, 18 to 50 years) who werediagnosed with FM according to the American College of Rheumatology criteria and 43 healthy female subjects (mean age 23.93±4.22 years;range, 18 to 50 years). Serum levels of TNF-α, IL-1β, IL-8, and Ox-LDL were measured by enzyme-linked immunosorbent assay in both groups.Fibromyalgia Impact Questionnaire, visual analog scale, symptom severity scale, and widespread pain index were carried out and also theirrelationships with TNF-α, IL-1β, IL-8, and Ox-LDL levels were evaluated.Results: There was no difference in levels of the serum TNF-α, IL-1β, IL-8, and Ox-LDL between FM patients and healthy controls (p>0.05). The severityof pain was significantly associated with TNF-α (r=0.338; p=0.021) and IL-8 (r=0.299; p=0.043) levels, and Ox-LDL (r=0.415; p=0.006) level was foundto be related to symptom severity of FM.Conclusion: Our results suggest that serum levels of TNF-α and IL-8 may be involved in the occurrence of pain in FM. The level of Ox-LDL may playan important role in the severity of symptoms. Future studies are needed to determine whether and how Ox-LDL plays a role in FM.
Anahtar Kelime: Konular:
Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- 1. Mease P. Fibromyalgia syndrome: review of clinical presentation, pathogenesis, outcome measures, and treatment. Rheumatol Suppl 2005;75:6-21.
- 2. Pernambuco AP, Leite Schetino LP, Cota Carvalho LDS, Reis DD. Involvement of oxidative stress and nitric oxide in fibromyalgia. Fibrom Open Access 2016;1:1000105.
- 3. Ang DC, Moore MN, Hilligoss J, Tabbey R.MCP-1 and IL-8 as pain biomarkers in fibromyalgia: a pilot study. Pain Med 2011;12:1154-61.
- 4. Wallace DJ, Margolin K, Waller P.Fibromyalgia and interleukin-2 therapy for malignancy. Ann Intern Med 1988;108:909.
- 5. Uçeyler N, Häuser W, Sommer C. Systematic review with meta-analysis: cytokines in fibromyalgia syndrome. BMC Musculoskelet Disord 2011;12:245.
- 6. Staud R.Cytokine and immune system abnormalities in fibromyalgia and other central sensitivity syndromes. Curr Rheumatol Rev 2015;11:109-15.
- 7. Bazzichi L, Rossi A, Massimetti G, Giannaccini G, Giuliano T, De Feo F, et al. Cytokine patterns in fibromyalgia and their correlation with clinical manifestations. Clin Exp Rheumatol 2007;25:225-30.
- 8. Rodriguez-Pintó I, Agmon-Levin N, Howard A, Shoenfeld Y. Fibromyalgia and cytokines. Immunol Lett 2014;161:200-3.
- 9. Xiao Y, Haynes WL, Michalek JE, Russell IJ. Elevated serum high-sensitivity C reactive protein levels in fibromyalgia syndrome patients correlate with body mass index, interleukin-6, interleukin-8, erythrocyte sedimentation rate. Rheumatol Int 2013;33:1259-64.
- 10. Ranzolin A, Duarte AL, Bredemeier M, da Costa Neto CA, Ascoli BM, Wollenhaupt-Aguiar B, et al. Evaluation of cytokines, oxidative stress markers and brain-derived neurotrophic factor in patients with fibromyalgia - A controlled cross-sectional study. Cytokine 2016;84:25-8.
- 11. Chung CP, Titova D, Oeser A, Randels M, Avalos I, Milne GL, et al. Oxidative stress in fibromyalgia and its relationship to symptoms. Clin Rheumatol 2009;28:435-8.
- 12. Ozgocmen S Ozyurt H, Sogut S, Akyol O, Ardicoglu O, Yildizhan H. Antioxidant status, lipid peroxidation and nitric oxide in fibromyalgia: etiologic and therapeutic concerns. Rheumatol Int 2006;26:598-603.
- 13. Tekin IO, Orem A, Shiri-Sverdlov R. Oxidized LDL in inflammation: from bench to bedside. Mediators Inflamm 2013;2013:762759.
- 14. Greig FH, Kennedy S, Spickett CM. Physiological effects of oxidized phospholipids and their cellular signaling mechanisms in inflammation. Free Radic Biol Med 2012;52:266-80.
- 15. Shen Y, Yang T, Guo S, Li X, Chen L, Wang T, et al. Increased serum ox-LDL levels correlated with lung function, inflammation, and oxidative stress in COPD. Mediators Inflamm 2013;2013:972347.
- 16. Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Katz RS, Mease P, et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res (Hoboken) 2010;62:600-10.
- 17. Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, et al. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 1990;33:160-72.
- 18. Burckhardt CS, Clark SR, Bennett RM. The fibromyalgia impact questionnaire: development and validation. J Rheumatol 1991;18:728-33.
- 19. Sarmer S, Ergin S, Yavuzer G. The validity and reliability of the Turkish version of the Fibromyalgia Impact Questionnaire. Rheumatol Int 2000;20:9-12.
- 20. Wang H, Moser M, Schiltenwolf M, Buchner M. Circulating cytokine levels compared to pain in patients with fibromyalgia -- a prospective longitudinal study over 6 months. J Rheumatol 2008;35:1366-70.
- 21. Mendieta D, De la Cruz-Aguilera DL, Barrera- Villalpando MI, Becerril-Villanueva E, Arreola R, Hernández-Ferreira E, et al. IL-8 and IL-6 primarily mediate the inflammatory response in fibromyalgia patients. J Neuroimmunol 2016;290:22-5.
- 22. Wallace DJ, Linker-Israeli M, Hallegua D, Silverman S, Silver D, Weisman MH.Cytokines play an aetiopathogenetic role in fibromyalgia: a hypothesis and pilot study. Rheumatology (Oxford) 2001;40:743-9.
- 23. Malek H, Ebadzadeh MM, Safabakhsh R, Razavi A, Zaringhalam J. Dynamics of the HPA axis and inflammatory cytokines: Insights from mathematical modeling. Comput Biol Med 2015;67:1-12.
- 24. Gur A, Karakoc M, Erdogan S, Nas K, Cevik R, Sarac AJ. Regional cerebral blood flow and cytokines in young females with fibromyalgia. Clin Exp Rheumatol 2002;20:753-60.
- 25. Kadetoff D, Lampa J, Westman M, Andersson M, Kosek E. Evidence of central inflammation in fibromyalgia-increased cerebrospinal fluid interleukin-8 levels. J Neuroimmunol 2012;242:33-8.
- 26. Uçeyler N, Valenza R, Stock M, Schedel R, Sprotte G, Sommer C. Reduced levels of antiinflammatory cytokines in patients with chronic widespread pain. Arthritis Rheum 2006;54:2656-64.
- 27. Gür A, Karakoç M, Nas K, Remzi, Cevik, Denli A, et al. Cytokines and depression in cases with fibromyalgia. J Rheumatol 2002;29:358-61.
- 28. Dinarello CA. Interleukin-1, interleukin-1 receptors and interleukin-1 receptor antagonist. Int Rev Immunol 1998;16:457-99.
- 29. Hernandez ME, Becerril E, Perez M, Leff P, Anton B, Estrada S, et al. Proinflammatory cytokine levels in fibromyalgia patients are independent of body mass index. BMC Res Notes 2010;3:156.
- 30. Bradley JR.TNF-mediated inflammatory disease. J Pathol 2008;214:149-60.
- 31. Jin W, Zhao Y, Yan W, Cao L, Zhang W, Wang M, et al. Elevated circulating interleukin-27 in patients with coronary artery disease is associated with dendritic cells, oxidized low-density lipoprotein, and severity of coronary artery stenosis. Mediators Inflamm 2012;2012:506283
- 32. Cordero MD, Alcocer-Gómez E, Cano-García FJ, De Miguel M, Carrión AM, Navas P, et al. Clinical symptoms in fibromyalgia are better associated to lipid peroxidation levels in blood mononuclear cells rather than in plasma.PLoS One 2011;6:26915.
- 33. La Rubia M, Rus A, Molina F, Del Moral ML. Is fibromyalgia-related oxidative stress implicated in the decline of physical and mental health status? Clin Exp Rheumatol 2013;31:121-7.
| APA | KUTU F, ÖZDOLAP ÇOBAN Ş, SARIKAYA S (2019). Pro-inflammatory Cytokines and Oxidized Low-Density-Lipoprotein in Patients With Fibromyalgia. , 123 - 129. 10.5606/ArchRheumatol.2019.6733 |
| Chicago | KUTU Funda Canpolat,ÖZDOLAP ÇOBAN ŞENAY,SARIKAYA Selda Pro-inflammatory Cytokines and Oxidized Low-Density-Lipoprotein in Patients With Fibromyalgia. (2019): 123 - 129. 10.5606/ArchRheumatol.2019.6733 |
| MLA | KUTU Funda Canpolat,ÖZDOLAP ÇOBAN ŞENAY,SARIKAYA Selda Pro-inflammatory Cytokines and Oxidized Low-Density-Lipoprotein in Patients With Fibromyalgia. , 2019, ss.123 - 129. 10.5606/ArchRheumatol.2019.6733 |
| AMA | KUTU F,ÖZDOLAP ÇOBAN Ş,SARIKAYA S Pro-inflammatory Cytokines and Oxidized Low-Density-Lipoprotein in Patients With Fibromyalgia. . 2019; 123 - 129. 10.5606/ArchRheumatol.2019.6733 |
| Vancouver | KUTU F,ÖZDOLAP ÇOBAN Ş,SARIKAYA S Pro-inflammatory Cytokines and Oxidized Low-Density-Lipoprotein in Patients With Fibromyalgia. . 2019; 123 - 129. 10.5606/ArchRheumatol.2019.6733 |
| IEEE | KUTU F,ÖZDOLAP ÇOBAN Ş,SARIKAYA S "Pro-inflammatory Cytokines and Oxidized Low-Density-Lipoprotein in Patients With Fibromyalgia." , ss.123 - 129, 2019. 10.5606/ArchRheumatol.2019.6733 |
| ISNAD | KUTU, Funda Canpolat vd. "Pro-inflammatory Cytokines and Oxidized Low-Density-Lipoprotein in Patients With Fibromyalgia". (2019), 123-129. https://doi.org/10.5606/ArchRheumatol.2019.6733 |
| APA | KUTU F, ÖZDOLAP ÇOBAN Ş, SARIKAYA S (2019). Pro-inflammatory Cytokines and Oxidized Low-Density-Lipoprotein in Patients With Fibromyalgia. Archives of Rheumatology, 34(2), 123 - 129. 10.5606/ArchRheumatol.2019.6733 |
| Chicago | KUTU Funda Canpolat,ÖZDOLAP ÇOBAN ŞENAY,SARIKAYA Selda Pro-inflammatory Cytokines and Oxidized Low-Density-Lipoprotein in Patients With Fibromyalgia. Archives of Rheumatology 34, no.2 (2019): 123 - 129. 10.5606/ArchRheumatol.2019.6733 |
| MLA | KUTU Funda Canpolat,ÖZDOLAP ÇOBAN ŞENAY,SARIKAYA Selda Pro-inflammatory Cytokines and Oxidized Low-Density-Lipoprotein in Patients With Fibromyalgia. Archives of Rheumatology, vol.34, no.2, 2019, ss.123 - 129. 10.5606/ArchRheumatol.2019.6733 |
| AMA | KUTU F,ÖZDOLAP ÇOBAN Ş,SARIKAYA S Pro-inflammatory Cytokines and Oxidized Low-Density-Lipoprotein in Patients With Fibromyalgia. Archives of Rheumatology. 2019; 34(2): 123 - 129. 10.5606/ArchRheumatol.2019.6733 |
| Vancouver | KUTU F,ÖZDOLAP ÇOBAN Ş,SARIKAYA S Pro-inflammatory Cytokines and Oxidized Low-Density-Lipoprotein in Patients With Fibromyalgia. Archives of Rheumatology. 2019; 34(2): 123 - 129. 10.5606/ArchRheumatol.2019.6733 |
| IEEE | KUTU F,ÖZDOLAP ÇOBAN Ş,SARIKAYA S "Pro-inflammatory Cytokines and Oxidized Low-Density-Lipoprotein in Patients With Fibromyalgia." Archives of Rheumatology, 34, ss.123 - 129, 2019. 10.5606/ArchRheumatol.2019.6733 |
| ISNAD | KUTU, Funda Canpolat vd. "Pro-inflammatory Cytokines and Oxidized Low-Density-Lipoprotein in Patients With Fibromyalgia". Archives of Rheumatology 34/2 (2019), 123-129. https://doi.org/10.5606/ArchRheumatol.2019.6733 |
